NCT05485818: Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction |
|
|
| Completed | 2a | 62 | RoW | Low Dose, NL005（ Low Dose）, Middle Dose, NL005（ Middle Dose）, High Dose, NL005（High Dose）, Placebo | Beijing Northland Biotech. Co., Ltd. | Acute Myocardial Infarction | 09/21 | 11/21 | | |
NCT01311518: A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction |
|
|
| Withdrawn | 2 | 0 | NA | Drug: Placebo, 0.00% Thymosin Beta 4, Drug: Injectable Thymosin beta 4, Injectable Thymosin Beta 4, Tβ4 Injectable Solution, RGN-352 | RegeneRx Biopharmaceuticals, Inc. | Acute Myocardial Infarction, ST Elevation Myocardial Infarction, STEMI | 07/20 | 07/20 | | |
